OR WAIT 15 SECS
ASHBURN, Va. -- Innocoll, Inc., a privately held specialty pharmaceutical company, announced that the first of two phase 3 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) Gentamicin Surgical Implant for the prevention of surgical site infections, has commenced dosing.
Gentamicin Surgical Implant is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) directly to the target tissue for localized action, while maintaining low systemic levels well below the toxicity threshold. The product was developed using Innocoll's proprietary collagen-based drug delivery technology, CollaRx, and (outside of the U.S.) is indicated as an adjunct to systemic antibiotic therapy for the treatment of localized, deep tissue infections and the prevention of surgical site infections in both hard and soft tissues.
Gentamicin Surgical Implant is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and there are more than 60 prospective clinical trials and published case reports totaling more than 7,500 patients documenting its safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures.
Following a pre-IND meeting with the FDA earlier this year, Innocoll will conduct two multi-centered phase 3 clinical trials in the U.S. to support the planned New Drug Application (NDA); the first in cardiac surgery patients at higher risk of surgical site infection and the second, expected to start later this month, in patients undergoing open colorectal surgery, which is considered to be the category most prone to surgical site infection. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the study coordinating center for both trials. Approximately 50 sites will be recruited for the trial in patients undergoing cardiac surgery and 35 sites for the colorectal surgery trial.
The cardiac surgery trial will enroll diabetic and/or obese (BMI>30) patients known to be at a higher risk of sternal wound infections, a serious and potentially life-threatening complication of cardiac surgery. The trial design is based upon a published 2,000 patient clinical trial demonstrating that the implant significantly reduced the incidence of sternal wound infection (SWI) by 53 percent when used as an adjunct to standard infection prophylaxis. This was a prospective, randomized, controlled clinical study performed at two hospital centers in Sweden and led by Dr. Orjan Friberg, cardiothoracic surgeon at Orebro University Hospital. Patients in the treatment group had two Gentamicin Implants (260 mg total dose) placed between the sternal halves before closure. The primary endpoint (total incidence of SWIs afterÂ two months post-surgery) was 9.0 percent in the control group and 4.3 percent in the treatment group (p<0.001). Sub-population analysis of known high-risk groups showed even greater treatment effect; including a 68 percent reduction in infection from 17.3 percent in the control group to 5.6 percent in the treatment group for patients with diabetes. Using the data generated in this cardiac surgery trial, a health economic analysis was performed and published showing that routine prophylactic use of the Gentamicin Surgical Implant resulted in a net cost saving per patient.
The design of the second trial in patients undergoing colorectal surgery is based upon an approved and well established use of Gentamicin Surgical Implant for this indication in Europe. Several such studies have been published, including one prospective, randomized, controlled clinical trial in 221 patients which demonstrated a 70 percent decrease in surgical site infections from 18.4 percent in the control group to 5.6 percent in the patients treated with the implant.
Source: Innocoll, Inc.